Compare HNVR & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | TTRX |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 281.2M |
| IPO Year | 2022 | N/A |
| Metric | HNVR | TTRX |
|---|---|---|
| Price | $24.66 | $10.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $24.50 | $8.00 |
| AVG Volume (30 Days) | 65.3K | ★ 100.3K |
| Earning Date | 04-27-2026 | 05-31-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $99.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $2.57 |
| 52 Week High | $25.61 | $11.69 |
| Indicator | HNVR | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.71 | 70.79 |
| Support Level | $22.09 | $3.28 |
| Resistance Level | N/A | $11.69 |
| Average True Range (ATR) | 0.72 | 1.12 |
| MACD | 0.15 | 0.06 |
| Stochastic Oscillator | 70.09 | 66.13 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.